Candidate is 10x more sensitive to target peptide than competitor candidates
Candidate is 10x more sensitive to target peptide than competitor candidates
Entry into the clinic in 2024
Selection of approaches from next-gen toolbox in development
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 8, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, provides a progress update on its PRAME program (ADP-600).
Jo Brewer Adaptimmune Chief Scientific Officer: “We have taken everything we know about design and development of TCRs to make a potent engineered TCR targeting PRAME with 10-fold greater peptide sensitivity than other competitor candidates. ADP-600 exhibits excellent potency and safety in preclinical assessments, and we plan to move this TCR into the clinic in 2024. We anticipate that combining this TCR with our next-gen approaches will create a best-in-class product.”
The PRAME antigen is highly expressed in many tumor types including endometrial carcinoma, ovarian carcinoma, melanoma, and synovial sarcoma and is validated as a target by other clinical candidates. Adaptimmune’s PRAME program presents a considerable opportunity to bring a best-in-class engineered TCR T-cell therapy to a wide range of people with solid tumor cancers.
The first-generation clinical candidate, designated ADP-600, was identified through Adaptimmune’s proprietary preclinical testing program to investigate the safety, specificity and potency of T-cells expressing engineered T-cell receptors (TCRs). This will support an IND submission to progress the Company’s PRAME program to an initial Phase 1 clinical trial to evaluate the safety of ADP-600 in multiple tumor types.
ADP-600 TCR demonstrates 10-fold greater peptide sensitivity than competitor clinical candidates. TCR sensitivity to its target is a key driver of TCR signaling and ability to respond to 10-fold lower target concentration indicates that T-cells expressing ADP-600 have the potential to be more effective in vivo.
T-cells expressing ADP-600 proliferate robustly in the presence of PRAME positive target cell lines and demonstrate cytotoxicity in in-vitro assays towards PRAME positive tumor cell lines, patient derived xenograft and primary tumor tissue.
The Company is evaluating multiple next-gen approaches using the same TCR. The next-gen approaches are intended to improve persistence and T-cell effectiveness (e.g., CD8α and membrane-bound IL-15) or help overcome the tumor microenvironment (e.g., PD-1 Switch technology).
The PRAME program will benefit from the application of Adaptimmune’s established vector and cell manufacturing facilities and clinical footprint. This program complements the Company’s existing validated clinical programs with MAGE-A4 and more information will be available on the program in 2024.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company’s unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2022, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/186385
